Skip to Main Content
Table 3.

Multivariate RR (95% CI) for the association between physical activity and breast cancer incidence among postmenopausal women according to selected tumor characteristics

Tumor characteristics*No. casesPhysical activity (times per week)
PtrendPheterogeneity
Inactive<11-23-4≥5
Hormone receptor status         
    ER+ 2,083 1.0 (Reference) 1.03 (0.89-1.19) 0.95 (0.83-1.08) 0.98 (0.86-1.11) 0.97 (0.84-1.12) 0.64 0.07 
    ER− 411 1.0 (Reference) 1.10 (0.81-1.49) 0.85 (0.63-1.14) 0.85 (0.64-1.12) 0.75 (0.54-1.04) 0.03  
         
    ER+/PR+ 1,649 1.0 (Reference) 1.00 (0.84-1.18) 0.97 (0.84-1.13) 0.96 (0.83-1.11) 0.96 (0.82-1.13) 0.53  
    ER+/PR− 338 1.0 (Reference) 1.29 (0.90-1.84) 0.93 (0.65-1.32) 1.17 (0.85-1.60) 1.05 (0.73-1.51) 0.85  
    ER−/PR+ 48 1.0 (Reference) 1.10 (0.41-2.95) 1.15 (0.47-2.78) 1.29 (0.56-2.95) 0.62 (0.21-1.86) 0.56 0.37 
    ER−/PR− 359 1.0 (Reference) 1.10 (0.80-1.53) 0.84 (0.61-1.15) 0.81 (0.60-1.10) 0.78 (0.55-1.10) 0.05  
    Unknown ER or PR 3,039 1.0 (Reference) 0.90 (0.80-1.02) 0.95 (0.85-1.06) 0.92 (0.83-1.01) 0.81 (0.72-0.91) 0.002  
         
Tumor stage         
    In situ 1,176 1.0 (Reference) 1.10 (0.91-1.33) 0.90 (0.75-1.08) 0.93 (0.78-1.10) 0.93 (0.77-1.13) 0.20 0.85 
    Invasive 5,433 1.0 (Reference) 0.97 (0.88-1.06) 0.95 (0.87-1.03) 0.94 (0.87-1.01) 0.86 (0.79-0.94) 0.001  
         
        Localized 3,158 1.0 (Reference) 0.97 (0.86-1.09) 0.95 (0.86-1.06) 1.00 (0.90-1.10) 0.85 (0.76-0.96) 0.04 0.17 
        Regional/distant 1,298 1.0 (Reference) 0.99 (0.83-1.17) 0.83 (0.71-0.98) 0.74 (0.63-0.86) 0.85 (0.71-1.01) 0.003 0.36 
Tumor histology         
    Ductal 3,568 1.0 (Reference) 0.98 (0.88-1.10) 0.96 (0.87-1.06) 0.93 (0.84-1.02) 0.89 (0.80-0.99) 0.02  
    Lobular 550 1.0 (Reference) 1.24 (0.95-1.63) 0.92 (0.71-1.19) 0.89 (0.69-1.14) 0.87 (0.65-1.15) 0.05 0.41 
    Ductal-lobular 436 1.0 (Reference) 0.80 (0.58-1.12) 0.80 (0.60-1.08) 0.95 (0.73-1.24) 0.89 (0.66-1.20) 0.96  
Tumor characteristics*No. casesPhysical activity (times per week)
PtrendPheterogeneity
Inactive<11-23-4≥5
Hormone receptor status         
    ER+ 2,083 1.0 (Reference) 1.03 (0.89-1.19) 0.95 (0.83-1.08) 0.98 (0.86-1.11) 0.97 (0.84-1.12) 0.64 0.07 
    ER− 411 1.0 (Reference) 1.10 (0.81-1.49) 0.85 (0.63-1.14) 0.85 (0.64-1.12) 0.75 (0.54-1.04) 0.03  
         
    ER+/PR+ 1,649 1.0 (Reference) 1.00 (0.84-1.18) 0.97 (0.84-1.13) 0.96 (0.83-1.11) 0.96 (0.82-1.13) 0.53  
    ER+/PR− 338 1.0 (Reference) 1.29 (0.90-1.84) 0.93 (0.65-1.32) 1.17 (0.85-1.60) 1.05 (0.73-1.51) 0.85  
    ER−/PR+ 48 1.0 (Reference) 1.10 (0.41-2.95) 1.15 (0.47-2.78) 1.29 (0.56-2.95) 0.62 (0.21-1.86) 0.56 0.37 
    ER−/PR− 359 1.0 (Reference) 1.10 (0.80-1.53) 0.84 (0.61-1.15) 0.81 (0.60-1.10) 0.78 (0.55-1.10) 0.05  
    Unknown ER or PR 3,039 1.0 (Reference) 0.90 (0.80-1.02) 0.95 (0.85-1.06) 0.92 (0.83-1.01) 0.81 (0.72-0.91) 0.002  
         
Tumor stage         
    In situ 1,176 1.0 (Reference) 1.10 (0.91-1.33) 0.90 (0.75-1.08) 0.93 (0.78-1.10) 0.93 (0.77-1.13) 0.20 0.85 
    Invasive 5,433 1.0 (Reference) 0.97 (0.88-1.06) 0.95 (0.87-1.03) 0.94 (0.87-1.01) 0.86 (0.79-0.94) 0.001  
         
        Localized 3,158 1.0 (Reference) 0.97 (0.86-1.09) 0.95 (0.86-1.06) 1.00 (0.90-1.10) 0.85 (0.76-0.96) 0.04 0.17 
        Regional/distant 1,298 1.0 (Reference) 0.99 (0.83-1.17) 0.83 (0.71-0.98) 0.74 (0.63-0.86) 0.85 (0.71-1.01) 0.003 0.36 
Tumor histology         
    Ductal 3,568 1.0 (Reference) 0.98 (0.88-1.10) 0.96 (0.87-1.06) 0.93 (0.84-1.02) 0.89 (0.80-0.99) 0.02  
    Lobular 550 1.0 (Reference) 1.24 (0.95-1.63) 0.92 (0.71-1.19) 0.89 (0.69-1.14) 0.87 (0.65-1.15) 0.05 0.41 
    Ductal-lobular 436 1.0 (Reference) 0.80 (0.58-1.12) 0.80 (0.60-1.08) 0.95 (0.73-1.24) 0.89 (0.66-1.20) 0.96  

NOTE: Multivariate models used age as the underlying time metric and were adjusted for race/ethnicity (White, Black, Hispanic, Asian/Pacific Islander/American Indian), education level (<12 years or high school equivalent, 12 years or high school equivalent, post-high school vocational or technical training, some college, college graduate, postgraduate), smoking status (nonsmoker, former, current), family history of breast cancer (no, yes), menopausal hormone use (never, current, past), age at first birth (nulliparous, <20, 20-24, 25-29, ≥30 years), age at menarche (<13, 13-14, ≥15 years), age at menopause (<40, 40-44, 45-49, 50-54, ≥55 years), parity (number of children: 0, 1-2, ≥3), and alcohol intake (g/d; quintiles adjusted for total energy intake).

*

Hormone receptor status and tumor histology limited to invasive cancers.

P value for comparison of in situ, localized, and regional/distant.

Close Modal

or Create an Account

Close Modal
Close Modal